Create Medicines secures $122M Series B to advance in vivo CAR-T therapies

Create Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases.

The round was co-led by existing backers Arch Venture Partners, Newpath Partners and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other investors.

The company's approach uses an mRNA-lipid nanoparticle system to deliver genetic instructions that reprogram T cells, NK cells and myeloid cells inside the body, enabling a one-day manufacturing process unlike traditional ex vivo cell therapies.

Founded in 2021 as Myeloid Therapeutics by Ronald Vale and Siddhartha Mukherjee, Create Medicines aims to leverage this technology to develop a pipeline of RNA-based CAR-T therapies for both oncology and autoimmune indications.